Fig. 1From: Preventive effects of galcanezumab in adult patients with episodic or chronic migraine are persistent: data from the phase 3, randomized, double-blind, placebo-controlled EVOLVE-1, EVOLVE-2, and REGAIN studiesEpisodic migraine: proportions of patients with maintenance of ≥ 50% response for ≥ 3 consecutive months until patient’s endpoint and response from month 1 to month 6. a maintenance of ≥ 50% response for ≥ 3 consecutive months. b maintenance of ≥ 50% response from month 1 to month 6. Abbreviations: OR = odds ratio. *** = p < 0.001Back to article page